Company profile
ARCUTIS BIOTHERAPEUTICS, INC.
NASDAQ:ARQTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZORYVE | approved | $129.9MQ2 2026 | 36 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03764475 | phase2 | completed | 2018-12-18 | 2020-10-08 | Arcutis Biotherapeutics, Inc. | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis |
| NCT04445987 | phase2 | completed | 2020-06-12 | 2022-11-19 | Arcutis Biotherapeutics, Inc. | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis |
| NCT07340216 | phase1 | completed | 2025-12-15 | 2026-04-30 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis |
| NCT04279119 | phase1 | completed | 2020-03-10 | 2021-03-25 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis |
| NCT04655313 | phase2 | completed | 2020-11-30 | 2022-01-12 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 217242 | 2023-12-15 | NDA | ARCUTIS BIOTHERAPEUTICS INC | |||||
Loading… | ||||||||
| NDA 215985 | 2022-07-29 | NDA | ARCUTIS BIOTHERAPEUTICS INC | |||||
Loading… | ||||||||